-
Mashup Score: 1Scott Kopetz, MD - KRYSTAL-1: Adagrasib-Cetuximab for KRASG12C CRC - 1 month(s) ago
Dr. Scott Kopetz discussed the KRYSTAL-1 study at AACR, presenting promising results of combining adagrasib and cetuximab to target KRASG12C mutated colorectal cancer, reporting a 34% response rate, with progression-free survival of 6.9 months and overall survival of 15.9 months in heavily pretreated patients.
Source: videos.oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Ajay Goel, PhD - Exosome Biopsy Detects Pancreatic Cancer - 1 month(s) ago
Dr. Ajay Goel presented a novel blood-based liquid biopsy for early detection of pancreatic cancer, utilizing a combination of microRNAs and exosomes to achieve a diagnostic accuracy of 92-97%. This approach, unique for its use of both cell-free and exosomal microRNAs, was validated across multiple international cohorts.
Source: videos.oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Ajay Goel, PhD - Exosome Biopsy Detects Pancreatic Cancer - 1 month(s) ago
Dr. Ajay Goel presented a novel blood-based liquid biopsy for early detection of pancreatic cancer, utilizing a combination of microRNAs and exosomes to achieve a diagnostic accuracy of 92-97%. This approach, unique for its use of both cell-free and exosomal microRNAs, was validated across multiple international cohorts.
Source: videos.oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 132024 Melanoma Updates - Justin T. Moyers, MD - MOASC 2024 - 2 month(s) ago
Justin T. Moyers, MD – Medical Oncology – The Angeles Clinic and Research Institute provides an overview of recent updates in melanoma treatment, including long-term follow-up results from the CHECKMATE-067 trial, adjuvant and neoadjuvant therapy studies, developments in adoptive cell therapy, and experimental treatments, presented at the MOASC 2024 Oncology Summit.
Source: videos.oncologytube.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Efficacy and Safety of Inotuzumab Ozogamicin - MOASC 2024 - 2 month(s) ago
Mojtaba Akhtari, MD, FACP-Professor of Medicine-Loma Linda University explains the Efficacy and Safety of Inotuzumab Ozogamicin – from the MOASC 2024 Advances in Oncology meeting in Newport B
Source: videos.oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Daratumumab: COVID-19 Impact - Robert Rifkin - ASH 2022 - 2 month(s) ago
Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and how did COVID-19 impact multiple myeloma Patients? So this is a very interesting study in that it utilizes the Connect Multiple Myeloma Registry (Connect® MM Registry). …
Source: videos.oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet
Video: Part 1 of 2 @skopetz @AACR Waun Ki Hong Award Recipient #AACR24 adagrasib + cetuximab in KRASG12C mutation. Part 2 = FDA acceleration see it here: https://t.co/RzI6qC1htk @MDAndersonNews https://t.co/8eyxxMoi6f